In a study with three UK academic institutions, the platform agreed with MDx results 94 percent of the time in detecting ...

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, ...

OK! can reveal King Charles has quietly resigned himself to what he sees as one of the great failures of his life, accepting the public story of his marriage to Princess Diana will never fully reflect ...

Molecular profiling guides ovarian cancer maintenance: HRD and BRCA results steer PARP inhibitors, bevacizumab choices, and patient counseling.

FDA clearance covers pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant disease after one or two prior systemic regimens, introducing PD-1 inhibition into this treatment ...

AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation (CDSCO) to sell and distribute Durvalumab solution for infusion used in ...

The FDA accepted the New Drug Application for zanzalintinib plus atezolizumab for the treatment of adult patients with metastatic colorectal cancer.

AstraZeneca receives approval to market Imfinzi in India for advanced endometrial cancer treatment, enhancing therapeutic options.

Researchers at the University of North Carolina at Chapel Hill have uncovered how chronic inflammation disrupts the immune ...

Researchers have uncovered the mechanisms behind three unique subtypes of mismatch repair deficient high-grade gliomas. The ...

AstraZeneca Pharma India has received CDSCO approval to sell and distribute Durvalumab (Imfinzi) for an additional cancer indication, expanding treatment options for endometrial cancer patients.